Masaru Matsuda, See Remarks at Arcutis Biotherapeutics, Inc. (ARQT), sold 12,058 shares at $25.70 ($314K) on 2026-03-02, disclosed to the SEC on 2026-03-03.
Scheduled sale ($314k) by See Remarks under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $27.95 | 3,325 | $93K | 29.6% |
| 2 | $25.16 | 6,553 | $165K | 52.5% |
| 3 | $25.70 | 1,987 | $51K | 16.3% |
| 4 | $25.91 | 193 | $5K | 1.6% |
| Total | $26.03 avg | 12,058 | $314K | 100% |
| Filing → |
| ARQT | SELL | 2026-08-05 | $32K | — | Filing → |
| ARQT | SELL | 2026-05-06 | $192K | — | Filing → |
| ARQT | SELL | 2026-02-04 | $1.2M | — | Filing → |